Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2010 1
2013 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Tyrosine supplementation for phenylketonuria.
Remmington T, Smith S. Remmington T, et al. Cochrane Database Syst Rev. 2021 Jan 4;1(1):CD001507. doi: 10.1002/14651858.CD001507.pub4. Cochrane Database Syst Rev. 2021. PMID: 33427303 Free PMC article.
SELECTION CRITERIA: All randomised or quasi-randomised trials investigating the use of tyrosine supplementation versus placebo in people with phenylketonuria in addition to, or instead of, a phenylalanine-restricted diet. People treated for maternal phenylketonuria …
SELECTION CRITERIA: All randomised or quasi-randomised trials investigating the use of tyrosine supplementation versus placebo in people wit …
Tyrosine supplementation for phenylketonuria.
Webster D, Wildgoose J. Webster D, et al. Cochrane Database Syst Rev. 2013 Jun 5;2013(6):CD001507. doi: 10.1002/14651858.CD001507.pub3. Cochrane Database Syst Rev. 2013. PMID: 23737086 Free PMC article. Updated. Review.
SELECTION CRITERIA: All randomised or quasi-randomised trials investigating the use of tyrosine supplementation versus placebo in people with phenylketonuria in addition to, or instead of, a phenylalanine-restricted diet. People treated for maternal phenylketonuria …
SELECTION CRITERIA: All randomised or quasi-randomised trials investigating the use of tyrosine supplementation versus placebo in people wit …
Tyrosine supplementation for phenylketonuria.
Webster D, Wildgoose J. Webster D, et al. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD001507. doi: 10.1002/14651858.CD001507.pub2. Cochrane Database Syst Rev. 2010. PMID: 20687067 Updated. Review.
SELECTION CRITERIA: All randomised or quasi-randomised trials investigating the use of tyrosine supplementation versus placebo in people with phenylketonuria in addition to, or instead of, a phenylalanine-restricted diet. People treated for maternal phenylketonuria …
SELECTION CRITERIA: All randomised or quasi-randomised trials investigating the use of tyrosine supplementation versus placebo in people wit …
Tyrosine supplementation for phenylketonuria.
Poustie VJ, Rutherford P. Poustie VJ, et al. Cochrane Database Syst Rev. 2000;(2):CD001507. doi: 10.1002/14651858.CD001507. Cochrane Database Syst Rev. 2000. PMID: 10796799 Updated. Review.
SELECTION CRITERIA: All randomised or pseudo-randomised trials investigating the use of tyrosine supplementation versus placebo in patients with phenylketonuria in addition to, or instead of, a phenylalanine restricted diet. Patients treated for maternal phenylketonuria …
SELECTION CRITERIA: All randomised or pseudo-randomised trials investigating the use of tyrosine supplementation versus placebo in patients …
Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American College of Medical Genetics and Genomics (ACMG).
Adams AD, Fiesco-Roa MÓ, Wong L, Jenkins GP, Malinowski J, Demarest OM, Rothberg PG, Hobert JA; ACMG Therapeutics Committee. Electronic address: documents@acmg.net. Adams AD, et al. Genet Med. 2023 Sep;25(9):100358. doi: 10.1016/j.gim.2022.12.005. Epub 2023 Jul 20. Genet Med. 2023. PMID: 37470789
PURPOSE: Elevated serum phenylalanine (Phe) levels due to biallelic pathogenic variants in phenylalanine hydroxylase (PAH) may cause neurodevelopmental disorders or birth defects from maternal phenylketonuria. New Phe reduction treatments have been approved in the l …
PURPOSE: Elevated serum phenylalanine (Phe) levels due to biallelic pathogenic variants in phenylalanine hydroxylase (PAH) may cause neurode …